Cardio-Obesity and Therapeutic Advances: Intersections Between Excess Adiposity, Cardiovascular Risk, and Pharmacologic Interventions - PubMed
8 days ago
- #Pharmacologic Therapy
- #Obesity
- #Cardiovascular Disease
- The review explores the connection between obesity and cardiovascular disease, focusing on new pharmacologic therapies.
- Incretin agonist therapies, like GLP-1 and GLP-1/GIP receptor agonists, are effective in weight loss and improving cardiometabolic health.
- Clinical trials show these medications reduce body weight by 10-20% and lower the risk of major cardiovascular events.
- Benefits are seen in patients with and without diabetes, extending beyond glycemic control.
- Tirzepatide shows superior efficacy in weight loss compared to GLP-1 monotherapy.
- Pharmacologic therapy is now a key part of managing obesity-related cardiovascular risk.
- New agents that aid weight loss and improve cardiovascular outcomes represent a paradigm shift in treatment.
- Early and sustained use of pharmacotherapy is recommended for high-risk individuals.
- Personalized care strategies are essential in obesity management.